KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Capital Expenditures (2016 - 2025)

Pacira BioSciences has reported Capital Expenditures over the past 16 years, most recently at -$13.6 million for Q4 2025.

  • Quarterly results put Capital Expenditures at -$13.6 million for Q4 2025, down 364.99% from a year ago — trailing twelve months through Dec 2025 was $1.5 million (down 73.62% YoY), and the annual figure for FY2025 was $1.5 million, down 73.62%.
  • Capital Expenditures for Q4 2025 was -$13.6 million at Pacira BioSciences, down from $3.9 million in the prior quarter.
  • Over the last five years, Capital Expenditures for PCRX hit a ceiling of $13.7 million in Q4 2023 and a floor of -$13.9 million in Q3 2022.
  • Median Capital Expenditures over the past 5 years was $2.2 million (2021), compared with a mean of $1.7 million.
  • Biggest five-year swings in Capital Expenditures: soared 3305.72% in 2023 and later plummeted 1741.18% in 2024.
  • Pacira BioSciences' Capital Expenditures stood at $2.1 million in 2021, then plummeted by 80.94% to $402000.0 in 2022, then soared by 3305.72% to $13.7 million in 2023, then plummeted by 62.38% to $5.1 million in 2024, then crashed by 364.99% to -$13.6 million in 2025.
  • The last three reported values for Capital Expenditures were -$13.6 million (Q4 2025), $3.9 million (Q3 2025), and $2.7 million (Q2 2025) per Business Quant data.